PDE FOR TRIETHYLAMINE AND METHYLISOBUTYLKETONE

IMPURITIES : RESIDUAL SOLVENTS (MAINTENANCE) PDE FOR TRIETHYLAMINE AND PDE OF METHYLISOBUTYLKETONE

TRIETHYLAMINE

Introduction

Triethylamine (TEA) is used as catalytic solvent in chemical synthesis (1,2). It is a colourless liquid that is soluble in water, ethanol, carbon tetrachloride, and ethyl ether, and very soluble in acetone, benzene, and chloroform. TEA has a vapour pressure of 54 mmHg (20°C), and has been reported to be irritating to the lung and nasal passage with strong ammoniac odour (2,3).

Data from human studies show that TEA is easily absorbed *via* the oral or inhalation route and is rapidly excreted, mainly in the urine, as the parent compound and/or its *N*-oxide (4-6).

In studies in human volunteers, exposures of more than 2.5 ppm (10 mg/m^3) caused transient visual disturbance (4,7) due to a locally induced cornea swelling; no systemic effects were observed at the exposures which showed the cornea effect. The odour thresholds ranged from 0.0022 to 0.48 mg/m^3 (8-10).

Genotoxicity

In an Ames test TEA did not induce mutations in standard Salmonella strains with or without metabolic activation (11). TEA did not induce sister chromatid exchanges in Chinese hamster ovary cells with or without metabolic activation (12). In an *in vivo* study, TEA induced aneuploidy but was not clastogenic in the bone marrow of rats exposed to 1 mg/m^3 (0.25 ppm) and 10 mg/m^3 (2.5 ppm) TEA *via* continuous inhalation for 30 or 90 days (13). The weak aneugenic effect was observed at the low dose and early time point only; due to study deficiencies the relevance of this finding is highly questionable. Overall, the available data do not provide evidence for a relevant genotoxic potential of TEA.

Carcinogenicity

No data available.

Reproductive toxicity

No reliable information about reproductive toxicity is available. A three-generation reproductive study in which rats (10/sex/group) were administered 0, 2, or 200 ppm (c.a. 0, 0.14 or 14 mg/kg/day) TEA in drinking water was cited in the United States Environmental Protection Agency (US EPA) Integrated Risk Information System assessment review (14). The high dose was increased to 500 ppm in the third

generation due to a lack of observed symptoms. No apparent effects occurred at 200 ppm through two generations. However, due to deficiencies in end-points measured the study data were disregarded from determining a Permitted Daily Exposure (PDE).

Repeated dose toxicity

A sub-chronic inhalation study (similar to Organisation for Economic Cooperation and Development [OECD] Test Guideline 413 and OECD Test Guideline 452) in rats is considered to be the most relevant published animal study for deriving a PDE. F344 rats (50 rats/group/sex) were exposed by whole body inhalation at concentrations of 0, 25, or 247 ppm (0, 0.10 or 1.02 mg/L) for 6 hours/day, 5 days/week for 28 weeks (15). No statistically significant treatment-related systemic effects were observed at all dose groups. Body weight gain was not statistically affected, although a slight dose-related decrease of body weight in male rats was observed. The No Observed Effect Level (NOEL) of this study was 247 ppm.

Molecular weight of TEA: 101.19 g/mol

NOEL 247 ppm

$$247 \text{ ppm} = \frac{247 \text{ x } 101.19}{24.45} = 1022.2 \text{ mg/m}^3 = 1.022 \text{ mg/L}$$

$$\text{For continuous dosing} = \frac{1.022 \text{ x } 6 \text{ x } 5}{24 \text{ x } 7} = 0.183 \text{ mg/L}$$

$$\text{Daily dose} = \frac{0.183 \text{mg L}^{-1} \text{ x } 290 \text{ L day}^{-1}}{0.425 \text{ kg}} = 124.9 \text{ mg/kg/day}$$

Rat respiratory volume: 290 L day^{-1}

Rat body weight: 0.425 kg

$$PDE = \frac{124.9 \text{ x } 50}{5 \text{ x } 10 \text{ x } 2 \text{ x } 1 \text{ x } 1} = 62.5 \text{ mg/day}$$

F1 = 5 to account for extrapolation from rats to humans

F2 = 10 to account for differences between individual humans

F3 = 2 because long duration of treatment (28 weeks)

F4 = 1 because no severe effects were observed

F5 = 1 because a NOEL was established

$$\text{Limit} = \frac{62.5 \times 1000}{10} = 6250 \text{ ppm}$$

Due to obvious study deficiencies other published animal toxicity data were disregarded from determining a PDE.

Conclusion

The calculated PDE for TEA based upon the NOEL of the rat sub-chronic inhalation study is 62.5 mg/day. Since the proposed PDE is greater than 50 mg/day it is recommended that TEA be placed into Class 3 ("solvents with low toxic potential") in Table 3 in the ICH Impurities: Residual Solvents Guideline.

References

1. Lide DR. CRC Handbook of Chemistry and Physics 86th ed. Boca Raton, FL, CRC Press, Taylor & Francis; 2005, p. 3-498.
2. Lewis RJ. Sr. Hawley's Condensed Chemical Dictionary 14th ed. New York: John Wiley & Sons; 2001, p. 1125.
3. OECD SIDS Initial Assessment Profile: Tertiary Amines. CoCAM 2, [Online]. 2012 April 17; Available from: URL: http://webnet.oecd.org/hpv/ui/Default.aspx
4. Akesson B, Skerfving S, Mattiasson L. Experimental study on the metabolism of triethylamine in man. Br J Ind Med 1988;45:262-8.
5. Akesson B, Vinge E, Skerfving S. Pharmacokinetics of triethylamine and triethylamine-N-oxide in man. Toxicol Appl Pharmacol 1989;100:529-38.
6. Akesson B, Skerfving S, Stahlbom B, Lundh T. Metabolism of triethylamine in polyurethane foam manufacturing workers. Am J Ind Med 1989;16:255-65.
7. Akesson B, Floren I, Skerfving S. Visual disturbances after experimental human exposure to triethylamine. Br J Ind Med 1985;42:848-50.
8. Amoore JE, Hautala E. Odor as an aid to chemical safety: Odor thresholds compared with threshold limit values and volatilities for 214 industrial chemicals in air and water dilution. J Appl Toxicol 1983;3:272-90.
9. Ruth JH. Odor thresholds and irritation levels of several chemical substances: A review. Am Ind Hyg Assoc J 1986;47:A142-A151.
10. Nagata Y. Measurement of odor threshold by triangle odor bag method. In: The Ministry of the Environment of Japan: Odor measurement review, Booklet of international workshop on odor measurement 2003;118-27.
11. Zeiger E, Anderson B, Haworth S, Lawlor T, Mortelmans K, Speck W. Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals. Environ Mutagen 1987;9:1-110.

12. Sorsa M, Pyy L, Salomaa S, Nylund L, Yager JW. Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mut Res 1988;204:465-79.
13. Isakova GE, Ekshtat BY, Kerkis YY. On studies of the mutagenic properties of chemical substances in the establishment of hygenic standards. Hygiene Saint 1971;36:178-84.
14. U.S EPA Integrated Risk Information System: Triethylamine (CASRN 121-44-8) [Online]. 1991 January 4; Available from: URL: http://www.epa.gov/iris/subst/0520.htm
15. Lynch DW, Moorman WJ, Lewis TR, Stober P, Hamlin R, Schueler RL. Subchronic inhalation of triethylamine vapor in Fisher-344 rats: Organ system toxicity. Toxicol Ind Health 1990;6:403-14.

Introduction

Methylisobutylketone (MIBK) is listed in the ICH Q3C parent Guideline of 1997 in Class 3, i.e., as a solvent with low toxicity based on a review of toxicity data available at that time resulting in a Permitted Daily Exposure (PDE) value for MIBK of 100 mg/day (1). Due to new toxicity data including results from National Toxicology Program (NTP) 2-year rat and mouse inhalation carcinogenicity studies and published studies on reproductive and developmental toxicity the Expert Working Group has re-evaluated the PDE value of MIBK.

Genotoxicity

No additional information about genotoxicity has been reported, since the last assessment was conducted in 1997. The available data suggest that MIBK is not genotoxic.

Carcinogenicity

MIBK has been studied by NTP in 2-year rat and mouse inhalation studies. F344/N rats and B6C3F1 mice (50 animals/sex/group) were exposed to MIBK at concentrations of 0, 450, 900, or 1800 ppm by inhalation, 6 hours per day, 5 days per week for two years. Survival was decreased in male rats at 1800 ppm (4). Body weight gains were decreased in male rats at 900 and 1800 ppm and in female mice at 1800 ppm. The primary targets of MIBK toxicity and carcinogenicity were the kidney in rats and the liver in mice. The NTP Technical Report concluded that there was some evidence of carcinogenic activity of MIBK in rats and mice (4,5). Based on these NTP data, IARC has classified MIBK as a group 2B carcinogen ("possibly carcinogenic to humans") (6).

In the rat NTP study, MIBK caused an increase in Chronic Progressive Nephropathy (CPN) and a slight increase in the incidences of renal tubule adenoma and carcinomas in males at the highest dose. Further mechanistic studies provide clear evidence that the renal tubular tumors in male rats are most likely caused through the well-known male rat specific α2u-nephropathy-mediated mode of action, which is considered to be without relevance to humans (7). Exacerbated CPN was also observed in female rats (increases in the incidence of CPN in all exposure concentrations and in the severity at 1800 ppm) the human relevance of which is currently unclear. Increases in mononuclear cell leukemias in male rats at 1800 ppm and the occurrence of two renal mesenchymal tumors (very rare tumor, not observed in NTP historical control animals) in female rats at 1800 ppm were findings with uncertain relationship to MIBK exposure (5).

From the results of the rat carcinogenicity study with MIBK, PDEs are calculated based on two different scenarios:

(i) tumor findings in male and female rats are not treatment-related and/or not relevant to humans and therefore the CPN in female rats observed at the lowest dose (LOEL[1] = 450 ppm) is used for PDE calculation.

or

(ii) relationship to MIBK exposure and relevance of rat tumor findings at 1800 ppm in males (mononuclear cell leukemias) and/or females (renal mesenchymal tumors) to humans cannot be excluded; the NOEL for tumors of 900 ppm is used for PDE calculation.

Molecular weight of MIBK: 100.16 g/mol

Scenario 1: $LOEL_{(CPN)}$ 450 ppm (rat)

$$450 \, \text{ppm} = \frac{450 \times 100.16}{24.45} = 1843 \, \text{mg/m}^3 = 1.843 \, \text{mg/L}$$

$$\text{For continuous dosing} = \frac{1.843 \times 6 \times 5}{24 \times 7} = 0.329 \, \text{mg/L}$$

$$\text{Daily dose} = \frac{0.329 \, \text{mg L}^{-1} \times 290 \, \text{L day}^{-1}}{0.425 \, \text{kg}} = 225 \, \text{mg/kg/day}$$

Rat respiratory volume: 290 L day^{-1}

Rat body weight: 0.425 kg

$$PDE = \frac{225 \times 50}{5 \times 10 \times 1 \times 1 \times 5} = 45 \, \text{mg/day}$$

F1 = 5 to account for extrapolation from rats to humans

F2 = 10 to account for differences between individual humans

F3 = 1 because long duration of treatment (2 years)

---

[1] Lowest Observed Effect Level

F4 = 1 low severity of effect (CPN in females) with unclear relevance for humans

F5 = 5 because a NOEL for CPN was not established

$$\text{Limit} = \frac{45 \times 1000}{10} = 4500 \text{ ppm}$$

Scenario 2: $\text{NOEL}_{(tumor)}$ 900 ppm (rat)

$$900 \text{ ppm} = \frac{900 \times 100.16}{24.45} = 3687 \text{ mg/m}^3 = 3.687 \text{ mg/L}$$

$$\text{For continuous dosing} = \frac{3.687 \times 6 \times 5}{24 \times 7} = 0.658 \text{ mg/L}$$

$$\text{Daily dose} = \frac{0.658 \text{ mg L}^{-1} \times 290 \text{ L day}^{-1}}{0.425 \text{ kg}} = 449 \text{ mg/kg/day}$$

Rat respiratory volume: 290 L day^{-1}

Rat body weight: 0.425 kg

$$PDE = \frac{449 \times 50}{5 \times 10 \times 1 \times 10 \times 1} = 44.9 \text{ mg/day}$$

F1 = 5 to account for extrapolation from rats to humans

F2 = 10 to account for differences between individual humans

F3 = 1 because long duration of treatment (2 years)

F4 = 10 severity of endpoint (cancer)

F5 = 1 because a NOEL was established

$$\text{Limit} = \frac{44.9 \times 1000}{10} = 4490 \text{ ppm}$$

In the mouse study, MIBK increased the incidence of hepatocellular adenomas, and adenoma or carcinoma (combined) in male and female mice exposed to 1800 ppm. Further mechanistic studies provide clear evidence for a constitutive androstane receptor (CAR)-mediated mode of action (MOA) for the mouse liver tumors (8). Since this MOA has been identified as not relevant for humans (9), no PDE calculation was done based on the mouse 2-year study data.

Reproductive and developmental toxicity

In a developmental toxicity study, pregnant F-344 rats were exposed to MIBK by inhalation at doses 0, 300, 1000, or 3000 ppm, 6 hours/day on gestational day 6 through 15. Some fetotoxicities (reduced fetal body weight and reductions in skeletal ossification) observed at 3000 ppm are considered to be secondary to maternal toxicities. There was no maternal, embryo, or fetal toxicity at 1000 ppm (2).

In a two-generation reproduction study, SD rats were exposed to MIBK *via* whole-body inhalation at concentrations of 0, 500, 1000, or 2000 ppm, 6 hours/day, for 70 days covering the period prior to mating of F0 generation through the lactation period of F2 generation. The NOEL for reproductive effects was 2000 ppm, the highest concentration tested; the NOEL for neonatal toxicity was 1000 ppm, based on acute Central Nervous System depressive effects (3).

Conclusion

The former PDE of MIBK was greater than 50 mg/day (100 mg/day) and the solvent was placed in Class 3. The newly calculated PDE of MIBK is based upon the NOEL for tumors in male and female rats and the LOEL for chronic progressive nephropathy in female rats from the NTP 2-year inhalation study; in both cases a PDE of 45 mg/day was calculated. Therefore, it is recommended that MIBK be placed into Class 2 in Table 2 in the ICH Impurities: Residual Solvents Guideline.

References

1. Connelly JC, Hasegawa R, McArdle JV, Tucker ML. ICH Guideline Residual Solvents. Pharmeuropa 1997;Suppl 9:57.
2. Tyl RW, France KA, Fisher LC, Pritts IM, Tyler TR, Phillips RD, et al. Developmental toxicity evaluation of inhaled methyl isbutyl ketone in Fisher 344 rats and CD-1 Mice. Fundam Appl Toxicol 1987;8:310-27.
3. Nemec MD, Pitt JA, Topping DC, Gingell R, Pavkov KL, Rauckman EJ, et al. Inhalation two-generation reproductive toxicity study of methyl isobutyl ketone in rats. Int J Toxicol 2004;23:127-43.
4. NTP. Toxicology and Carcinogenesis Studies of Methyl Isobutyl Ketone (CAS No. 108-10-1) in F344/N Rats and B6C3F1 Mice (Inhalation Studies). US Department of Health and Human Services, Public Health Service, National Institutes of Health; Research Triangle Park, NC: 2007. Technical Report Series No. 538.
5. Stout MD, Herbert RA, Kissling GE, Suarez F, Roycroft JH, Chhabra RS et al. Toxicity and carcinogenicity of methyl isobutyl ketone in F344N rats and

B6C3F1 mice following 2-year inhalation exposure. Toxicology 2008;244:209–19.

6. IARC. Some Chemicals Present in Industrial and Consumer Products, Food and Drinking-water. IARC Monographs 2012;101:305-24.

7. Borghoff SJ, Poet TS, Green S, Davis J, Hughes B, Mensing T, et al. Methyl isobutyl ketone exposure-related increases in specific measures of α2u-globulin (α2u) nephropathy in male rats along with in vitro evidence of reversible protein binding. Toxicology 2015;333:1-13.

8. Hughes BJ, Thomas J, Lynch AM, Borghoff SJ, Green S, Mensing T, et al. Methyl isobutyl ketone-induced hepatocellular carcinogenesis in B6C3F(1) mice: A constitutive androstane receptor (Car) -mediated mode of action. Regul Toxicol Pharmacol. 2016;doi:10.1016/j.yrtph.2016.09.024. [Epub ahead of print] PubMed PMID: 27664318.

9. Elcombe CR, Peffer RC, Wolf DC, Bailey J, Bars R, Bell D, et al. Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator. Crit Rev Toxicol 2014;44:64-82.